Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Bio Joo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Dural Metastasis in Breast Cancer: MRI-Based Morphological Subtypes and Their Clinical Implications
Sung Jun Ahn, Bio Joo, Mina Park, Hun Ho Park, Sang Hyun Suh, Sung Gwe Ahn, Jihwan Yoo
Cancer Res Treat. 2024;56(4):1105-1112.   Published online March 19, 2024
DOI: https://doi.org/10.4143/crt.2024.138
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to investigate the clinical factors associated with breast cancer (BRCA) dural metastases (DMs), their impact on prognosis compared to brain parenchymal metastases (BPMs) alone, and differences between DM subtypes, aiming to inform clinical decisions.
Materials and Methods
We retrospectively analyzed 119 patients with BRCA with brain metastasis, including 91 patients with BPM alone and 28 patients with DM. Univariate and multivariate analyses were performed to compare the clinical characteristics between the two groups and within subtypes of DM. Overall survival after DM (OSDM) and the interval from DM to leptomeningeal carcinomatosis (LMC) were compared using Kaplan-Meier analysis.
Results
DM was notably linked with extracranial metastasis, luminal-like BRCA subtype (p=0.033), and skull metastases (p < 0.001). Multiple logistic regression revealed a strong association of DM with extracranial and skull metastases, but not with subtype or hormone receptor status. Patients with DM did not show survival differences compared with patients with BPM alone. In the subgroup analysis, nodular-type DM correlated with human epidermal growth factor receptor 2 status (p=0.044), whereas diffuse-type DM was significantly associated with a higher prevalence of the luminal-like subtype (p=0.048) and the presence of skull metastasis (p=0.002). Patients with diffuse DM did not exhibit a significant difference in OSDM but had a notably shorter interval from DM to LMC compared to those with nodular DM (p=0.049).
Conclusion
While the impact of DM on the overall prognosis of patients with BRCA is minimal, our findings underscore distinct characteristics and prognostic outcomes within DM subgroups.

Citations

Citations to this article as recorded by  
  • Small-cell neuroendocrine carcinoma of the cervix with leptomeningeal spread: A rare coincidence report and literature review
    Mohammed A. Azab, Oday Atallah, Nour El-Gohary, Ahmed Hazim, Hamed Abdelma’aboud Mostafa
    Surgical Neurology International.2024; 15: 310.     CrossRef
  • Left homonymous hemianopia as an atypical manifestation of isolated pachymeningeal metastasis secondary to breast cancer: Case report and review of the literature
    Aziz Ahizoune, Moad Belouad, Houda Alloussi, Mohamed Allaoui, Mohamed Hamid, Ahmed Bourazza
    Radiology Case Reports.2024; 19(11): 5459.     CrossRef
  • 1,246 View
  • 74 Download
  • 2 Crossref
Close layer
General
Clinicopathological Characteristics of NRG1 Fusion–Positive Solid Tumors in Korean Patients
Yoon Jin Cha, Chung Lee, Bio Joo, Kyung A Kim, Choong-kun Lee, Hyo Sup Shim
Cancer Res Treat. 2023;55(4):1087-1095.   Published online June 15, 2023
DOI: https://doi.org/10.4143/crt.2023.682
AbstractAbstract PDFPubReaderePub
Purpose
Neuregulin 1 (NRG1) gene fusion is a potentially actionable oncogenic driver. The oncoprotein binds to ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic approach for inhibiting ERBB3/ERBB2. However, the frequency and clinicopathological features of solid tumors harboring NRG1 fusions in Korean patients remain largely unknown.
Materials and Methods
We reviewed archival data from next-generation sequencing panel tests conducted at a single institution, specifically selecting patients with in-frame fusions that preserved the functional domain. The clinicopathological characteristics of patients harboring NRG1 fusions were retrospectively reviewed.
Results
Out of 8,148 patients, NRG1 fusions were identified in 22 patients (0.27%). The average age of the patients was 59 years (range, 32 to 78 years), and the male-to-female ratio was 1:1.2. The lung was the most frequently observed primary site (n=13), followed by the pancreaticobiliary tract (n=3), gastrointestinal tract (n=2, stomach and rectum each), ovary (n=2), breast (n=1), and soft tissue (n=1). Histologically, all tumors demonstrated adenocarcinoma histology, with the exception of one case of sarcoma. CD74 (n=8) and SLC3A2 (n=4) were the most frequently identified fusion partners. Dominant features included the presence of fewer than three co-occurring genetic alterations, a low tumor mutation burden, and low programmed death-ligand 1 expression. Various clinical responses were observed in patients with NRG1 fusions.
Conclusion
Despite the rarity of NRG1 fusions in Korean patients with solid tumors, identification through next-generation sequencing enables the possibility of new targeted therapies.

Citations

Citations to this article as recorded by  
  • Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors
    Chunwei Xu, Qian Wang, Dong Wang, Wenxian Wang, Wenfeng Fang, Ziming Li, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfen
    Global Medical Genetics.2024; 11(01): 086.     CrossRef
  • Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer
    Hongyan Li, Lina Xu, Hongshun Cao, Tianyi Wang, Siwen Yang, Yixin Tong, Linlin Wang, Qiang Liu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
    Jasmine Vargas, Georgios Pantouris
    International Journal of Molecular Sciences.2023; 24(21): 15981.     CrossRef
  • 3,835 View
  • 241 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
Yeo-Eun Kim, Bio Joo, Mi-Suk Park, Sang Joon Shin, Joong Bae Ahn, Myeong-Jin Kim
Cancer Res Treat. 2016;48(4):1210-1221.   Published online March 17, 2016
DOI: https://doi.org/10.4143/crt.2015.374
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and Methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests.
Results
The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.

Citations

Citations to this article as recorded by  
  • Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights
    Geetika Kaur, Bipradas Roy
    Biomedicines.2024; 12(4): 827.     CrossRef
  • Current trends in the characterization and monitoring of vascular response to cancer therapy
    Binita Shrestha, Noah B Stern, Annie Zhou, Andrew Dunn, Tyrone Porter
    Cancer Imaging.2024;[Epub]     CrossRef
  • Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases
    Martina Caruso, Arnaldo Stanzione, Anna Prinster, Laura Micol Pizzuti, Arturo Brunetti, Simone Maurea, Pier Paolo Mainenti
    World Journal of Gastroenterology.2023; 29(3): 521.     CrossRef
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition
    Brandon M. Bordeau, Joseph Ryan Polli, Ferdinand Schweser, Hans Peter Grimm, Wolfgang F. Richter, Joseph P. Balthasar
    International Journal of Molecular Sciences.2022; 23(2): 679.     CrossRef
  • The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids
    Sarah Line Bring Truelsen, Nabi Mousavi, Haoche Wei, Lucy Harvey, Rikke Stausholm, Erik Spillum, Grith Hagel, Klaus Qvortrup, Ole Thastrup, Henrik Harling, Harry Mellor, Jacob Thastrup, Christina L. Addison
    PLOS ONE.2021; 16(7): e0253258.     CrossRef
  • [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
    Rohini Sharma, Pablo Oriol Valls, Marianna Inglese, Suraiya Dubash, Michelle Chen, Hani Gabra, Ana Montes, Amarnath Challapalli, Mubarik Arshad, George Tharakan, Ed Chambers, Tom Cole, Jingky P. Lozano-Kuehne, Tara D. Barwick, Eric O. Aboagye
    European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(5): 1239.     CrossRef
  • Combination of DCE‐MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma
    Changmin Liu, Roger Sun, Jing Wang, Fangling Ning, Zhenbo Wang, Judong Luo, Shaoshui Chen, Shuanghu Yuan, Enzo Terreno
    BioMed Research International.2020;[Epub]     CrossRef
  • Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging
    Pier Paolo Mainenti, Arnaldo Stanzione, Salvatore Guarino, Valeria Romeo, Lorenzo Ugga, Federica Romano, Giovanni Storto, Simone Maurea, Arturo Brunetti
    World Journal of Gastroenterology.2019; 25(35): 5233.     CrossRef
  • Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients
    Matteo Morotti, Prashanth Hari Dass, Adrian L. Harris, Simon Lord
    European Journal of Drug Metabolism and Pharmacokinetics.2018; 43(2): 137.     CrossRef
  • Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
    Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile
    BMC Cancer.2018;[Epub]     CrossRef
  • Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases
    Pavitra Kannan, Warren W. Kretzschmar, Helen Winter, Daniel Warren, Russell Bates, Philip D. Allen, Nigar Syed, Benjamin Irving, Bartlomiej W. Papiez, Jakob Kaeppler, Bosjtan Markelc, Paul Kinchesh, Stuart Gilchrist, Sean Smart, Julia A. Schnabel, Tim Mau
    Clinical Cancer Research.2018; 24(19): 4694.     CrossRef
  • Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy
    Marie Mogensen, Martin Hansen, Birthe Henriksen, Thomas Axelsen, Ben Vainer, Kell Osterlind, Michael Nielsen
    Diagnostics.2017; 7(2): 35.     CrossRef
  • Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis
    Simonetta Geninatti Crich, Enzo Terreno, Silvio Aime
    Advanced Drug Delivery Reviews.2017; 119: 61.     CrossRef
  • 10,286 View
  • 147 Download
  • 14 Web of Science
  • 13 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP